479251-89-3

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 26150-46-9 cis,cis-1,3,5-triaminocyclohexane 
• 76-83-5 trityl chloride 
• 479251-79-1 N,N'-bis-trityl-cis,cis-1,3,5-triaminocyclohexane 

Downstream Products

• 479251-93-9 2-(4-{[(1S,3R,5S)-3,5-Bis-(trityl-amino)-cyclohexyl]-pyridin-2-ylmethyl-amino}-butyl)-isoindole-1,3-dione 
• 479251-91-7 N-ethyl-N-(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane 
• 479251-94-0 2-{4-[((1S,3R,5S)-3,5-Diamino-cyclohexyl)-pyridin-2-ylmethyl-amino]-butyl}-isoindole-1,3-dione 
• 479251-96-2 N-(4-aminobutyl)-N, N',N''-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane 
• 479251-95-1 2-[4-({(1S,3R,5S)-3,5-Bis-[(pyridin-2-ylmethyl)-amino]-cyclohexyl}-pyridin-2-ylmethyl-amino)-butyl]-isoindole-1,3-dione 
• 479251-90-6 N-ethyl-N-(2-pyridylmethyl)-N',N''-bis-trityl-cis,cis-1,3,5-triaminocyclohexane 

Relevant academic research and scientific papers

Synthesis of 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives as potential antitumor agents.

Iron deprivation has been previously proven to be a promising strategy in treating tumor cells. A series of cis,cis-1,3,5-triaminocyclohexane N-pyridyl derivatives as iron-depleting antitumor agents were prepared. Cytotoxic activity of these derivatives was evaluated in the HeLa cancer cell line. Among the tested derivatives, N-ethyl-N,N',N"-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane (17) exhibited potent cytotoxicity against this cancer cell line. On the basis of the structure of 17, a bifunctional iron chelator 24 was designed and prepared. Bifunctional agent 24 possessing a maleimide linker that is functional for conjugation to thiolated monoclonal antibodies is a promising lead compound for development of antitumor conjugates for antibody-targeted therapies.